These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21701440)

  • 1. Linagliptin (Tradjenta)--a new DPP-4 inhibitor for type 2 diabetes.
    Med Lett Drugs Ther; 2011 Jun; 53(1367):49-50. PubMed ID: 21701440
    [No Abstract]   [Full Text] [Related]  

  • 2. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
    Deacon CF; Holst JJ
    Expert Opin Investig Drugs; 2010 Jan; 19(1):133-40. PubMed ID: 19947894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Toth PP
    Postgrad Med; 2011 Jul; 123(4):46-53. PubMed ID: 21680988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
    Barnett AH
    Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
    Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
    Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
    Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
    Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.
    Neumiller JJ
    Ann Pharmacother; 2012 Mar; 46(3):358-67. PubMed ID: 22318932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes.
    Friedrich C; Emser A; Woerle HJ; Graefe-Mody U
    Am J Ther; 2013; 20(6):618-21. PubMed ID: 23411609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
    Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
    Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Oral Linagliptin (Trajenta)].
    Duh D; Tanret I
    J Pharm Belg; 2013 Mar; (1):41-3. PubMed ID: 23638612
    [No Abstract]   [Full Text] [Related]  

  • 12. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
    Forst T; Pfützner A
    Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).
    Graefe-Mody U; Friedrich C; Port A; Ring A; Retlich S; Heise T; Halabi A; Woerle HJ
    Diabetes Obes Metab; 2011 Oct; 13(10):939-46. PubMed ID: 21672124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1561-76. PubMed ID: 22022857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.
    Forst T; Uhlig-Laske B; Ring A; Graefe-Mody U; Friedrich C; Herbach K; Woerle HJ; Dugi KA
    Diabet Med; 2010 Dec; 27(12):1409-19. PubMed ID: 21059094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological and clinical profiles of the DPP-4 inhibitor linagliptin (Trazenta)].
    Ohmura T; Hayashi N; Encinas J
    Nihon Yakurigaku Zasshi; 2012 Apr; 139(4):174-83. PubMed ID: 22498683
    [No Abstract]   [Full Text] [Related]  

  • 17. Bioequivalence of Linagliptin 5 mg once daily and 2.5 mg twice daily: pharmacokinetics and pharmacodynamics in an open-label crossover trial.
    Friedrich C; Jungnik A; Retlich S; Ring A; Meinicke T
    Drug Res (Stuttg); 2014 May; 64(5):269-75. PubMed ID: 24154935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2013 Sep; 68(9):479-85. PubMed ID: 24180204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
    Barnett AH
    Expert Opin Drug Saf; 2015 Jan; 14(1):149-59. PubMed ID: 25351273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linagliptin: the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
    Aletti R; Cheng-Lai A
    Cardiol Rev; 2012; 20(1):45-51. PubMed ID: 22143285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.